M L Gershanovich
Overview
Explore the profile of M L Gershanovich including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
130
Citations
38
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Filatova L, Gershanovich M, Plotnikova A, Turkevich E, Ivantsov A, Klimashevskii V
Vopr Onkol
. 2015 Mar;
60(5):625-9.
PMID: 25816669
In order to identify immunohistochemical markers associated with primary refractory Hodgkin's lymphoma, 20 patients with primary refractory form at stage IIAB in complete remission underwent histological examination and immunohistochemical determination...
2.
Prevost V, Likhachev A, Loktionova N, Bartsch H, Wild C, Kazanova O, et al.
Biomarkers
. 2013 Jul;
1(4):244-51.
PMID: 23888991
Abstract Urinary 3-methyladenine (3-MeAde) excretion andlymphocyte DNA adduct formation was studied in 15 patients receiving methylnitrosourea (MNU) at several dose levels (250 mg, 300 mg and600 mg total dose, 143-385...
3.
Filatova L, Plotnikova A, Gershanovich M, Semiglazova T
Vopr Onkol
. 2013 Jul;
59(2):59-65.
PMID: 23814851
In a retrospective study during the primary mode MOPP to primary patients LH II/IVAB stages with a poor prognosis rate of CR, 5--and 10-year DFS, OS was 69%, 71% and...
4.
Filatova L, Tarasenkova A, Semiglazova T, Gershanovich M
Vopr Onkol
. 2013 Apr;
58(4):443-53.
PMID: 23607197
No abstract available.
5.
Filatova L, Tarasenkova A, Gershanovich M, Semiglazova T
Vopr Onkol
. 2013 Apr;
58(5):627-38.
PMID: 23600279
Retrospective analysis defined risk factors of primary-refractory course of Hodgkin's lymphoma as well as adverse prognostic factors, efficacy of I and II therapy lines in patients with primary-refractory forms of...
6.
Stukov A, Filatova L, Gershanovich M, Semiglazova T, Tarasenkova A, Latinova D, et al.
Vopr Onkol
. 2012 Aug;
58(3):394-7.
PMID: 22888657
SHR mice with intracranial transplanted lymphosarcoma LIO-1 received a single intraperitoneal gemcitabine injection in maximal tolerated dose of 25 mg/kg or single maximal tolerated oral dose of lomustine, 50 mg/kg....
7.
Filatova L, Tarasenkova A, Gershanovich M, Semiglazov T
Vopr Onkol
. 2012 Jul;
58(2):265-74.
PMID: 22774536
The retrospective study revealed the 15% relapse rate in patients with stage II-IV unfavorable prognosis Hodgkin lymphoma, 5-year OS in relapsed patients was 84%. Karnofsky score less than 80 (p=0,0001),...
8.
Tarasenkova A, Filatova L, Gershanovich M, Semiglazova T
Vopr Onkol
. 2012 May;
58(1):101-9.
PMID: 22629838
In this retrospective clinical study 100 patients with primary unfavorable prognosis stage II Hodgkin lymphoma (HL) (n = 50) or stage IV HL (n = 50). The ABVD chemotherapy allowed...
9.
Bespalov V, Beliaeva O, Panchenko A, Stukov A, Gershanovich M, Murazov I, et al.
Vopr Onkol
. 2012 Mar;
57(6):771-4.
PMID: 22416396
Antitumor activity of dioxadet in comparison with cisplatin was studied on the model of ascitic ovarian tumor in 32 female Wistar rats. Ascitic ovarian tumor was transplanted intraperitoneally 0.5 ml...
10.
Latipova D, Gershanovich M, Stukov A, Semiglazova T, Filatova L, Tarasenkova A, et al.
Vopr Onkol
. 2012 Mar;
57(6):767-70.
PMID: 22416395
Antitumor activity of a new cytostatic drug combination of gemcitabine and dioxadet have been studied in 86 female SHR mice transplanted with 5 x 10(6) of ascitic Ehrlich's tumor cells...